Immatics N.V. (IMTX) vs SL Science (SLBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immatics N.V. (IMTX) has outperformed SL Science (SLBT) over the past year, losing 28.9% versus a loss of 85.3%. Immatics N.V. is the larger company by market cap ($1.12 billion vs $852.4 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMTX | SLBT |
|---|---|---|
| Share price | $7.37 | $1.52 |
| Market cap | $1.12B | $852.35M |
| 1-day change | -1.07% | +0.66% |
| YTD return | -29.81% | -85.59% |
| 1-year return | -28.93% | -85.32% |
| 5-year return | -46.79% | — |
| EPS (TTM) | $-1.87 | $-0.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.41 | $14.50 |
| 52-week low | $7.02 | $1.42 |
| Distance from 52-week high | -40.61% | -89.52% |
| Analyst consensus | none | — |
| Avg. price target upside | +139.21% | — |
| Average volume | 600.13K | 80.48K |
| Shares outstanding | 152.23M | 560.76M |
| Employees | 704 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMTX has outperformed SLBT by 56.4 percentage points over the past year.
About Immatics N.V.
IMTX stock →Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 704 employees
About SL Science
SLBT stock →SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
IMTX vs SLBT FAQ
Which is bigger, Immatics N.V. or SL Science?
Immatics N.V. (IMTX) is larger, with a market capitalization of $1.12B compared with $852.35M for SL Science (SLBT).
Which stock has performed better over the past year, IMTX or SLBT?
IMTX returned -28.93% over the past 12 months, compared with -85.32% for SLBT (price return, excluding dividends). Past performance does not predict future results.
Are Immatics N.V. and SL Science in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.